Akebia Therapeutics' CEO on Mechanisms of HIF-PHI Candidate
Vadadustat is an investigational drug belonging to a class known as hypoxia-inducible prolyl hydroxylase inhibitors (HIF-PHIs) for the treatment of anemia in chronic kidney disease.
Watch video Akebia Therapeutics' CEO on Mechanisms of HIF-PHI Candidate online, duration hours minute second in high quality that is uploaded to the channel AJMCtv 23 October 2020. Share the link to the video on social media so that your subscribers and friends will also watch this video. This video clip has been viewed 1,823 times and liked it 12 visitors.
